SynthesisCancer immunology, immunotherapy : CII2022

First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.

Mingfeng He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.